Publications by authors named "Scott Wieland"
Importance: Standard therapy for advanced soft-tissue sarcoma has not changed substantially in decades, and patient prognosis remains poor. Aldoxorubicin, a novel albumin-binding prodrug of doxorubicin, showed clinical activity against advanced soft-tissue sarcoma in phase 1 studies.
Objective: To evaluate efficacy and safety of aldoxorubicin vs doxorubicin in patients with advanced soft-tissue sarcoma.
Introduction Aldoxorubicin, a prodrug of doxorubicin, binds covalently to serum albumin in the bloodstream and accumulates in tumors. Aldoxorubicin can be administered at doses several-fold higher than doxorubicin can, without associated acute cardiotoxicity. Purpose This study fully evaluated the pharmacokinetic profile of aldoxorubicin (serum and urine).
View Article and Find Full Text PDFGlioblastoma multiforme (GBM) is the most aggressive primary brain tumor with a median survival of 12 to 15 months after diagnosis. Acquired chemoresistance, high systemic toxicity, and low penetration of the blood brain barrier by many anticancer drugs contribute to the failure of anti-GBM therapies. To circumvent some of these obstacles, we tested a novel prodrug approach to evaluate anti-GBM efficacy by utilizing serum albumin-binding doxorubicin (Doxo), aldoxorubicin (Aldoxo), which is less toxic, is released from albumin in an acidic environment and accumulates in tumor tissues.
View Article and Find Full Text PDFBackground: Aldoxorubicin, a prodrug of doxorubicin, covalently binds to serum albumin, allowing for the administration of much higher doses of doxorubicin in a previous clinical study. The current phase 1B/2 study evaluated the safety of aldoxorubicin, including preliminary efficacy and safety of its maximum tolerated dose (MTD).
Methods: Patients aged 18 to 70 years with recurrent/refractory malignant solid tumors received aldoxorubicin at a dose of 230 mg/m(2) , 350 mg/m(2) , or 450 mg/m(2) (170 mg/m(2) , 260 mg/m(2) , or 335 mg/m(2) doxorubicin equivalents, respectively) by intravenous infusion once every 21 days for up to 8 consecutive cycles.
Arimoclomol: a potential therapy under development for ALS.
Expert Opin Investig Drugs
December 2009
Article Synopsis
- Arimoclomol is being studied as a potential treatment for amyotrophic lateral sclerosis (ALS) due to its ability to enhance heat shock protein expression, which helps cells respond to stress.
- Research indicates that arimoclomol can improve survival and muscle function in mouse models of ALS, and initial human safety studies support its use at doses up to 300 mg/day.
- Ongoing studies are exploring its effects in patients with familial ALS linked to specific genetic mutations, highlighting its promise as a therapeutic option for both sporadic and familial forms of the disease.
Article Synopsis
- The study involved 84 ALS participants who received arimoclomol in different doses or a placebo, focusing on assessing safety, tolerability, and how the drug is processed in the body.
- Results showed that arimoclomol was well-tolerated at doses up to 300 mg/day, effectively crosses the blood-brain barrier, and supports a dosing schedule of three times a day, paving the way for future efficacy studies.